3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
3
Phase 1
2
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Breast Neoplasms
9
Colorectal Neoplasms
2
Brain Neoplasms
2
Uterine Cervical Neoplasms
1
Stomach Neoplasms
1
Neoplasm Metastasis
1
HER2-positive Breast Cancer
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Adenocarcinoma Of Esophagus
1
Interventions
pembrolizumab
43
Nivolumab
24
Gemcitabine
23
Cyclophosphamide
22
Paclitaxel
17
Capecitabine
16
fludarabine
15
Ipilimumab
14
aldesleukin
11
Docetaxel
11
130-nm albumin-bound paclitaxel
11
Trastuzumab
10
Cetuximab
10
Bevacizumab
10
Albumin-Bound Paclitaxel
9
fludarabine phosphate
8
Specimen Handling
8
Interleukin-2
8
Fluorouracil
8
Cisplatin
8
Biopsy
8
Radiosurgery
7
Oxaliplatin
7
Irinotecan
7
durvalumab
6
avelumab
6
Temozolomide
6
Pemetrexed
6
Leucovorin
6
Carboplatin
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Neoplasm Metastasis
×
Ado-Trastuzumab Emtansine
×
Clear all
NCT05081609
2026-02-24
IL Believe
Ascendis Pharma A/S
Phase 1/2
Active not recruiting
320 enrolled